

Form 5500 Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Annual Return/Report of Employee Benefit Plan This form is required to be filed for employee benefit plans under sections 104 and 4065 of the Employee Retirement Income Security Act of 1974 (ERISA) and sections 6057(b) and 6058(a) of the Internal Revenue Code (the Code). ▶ Complete all entries in accordance with the instructions to the Form 5500.	OMB Nos. 1210-0110 1210-0089 2017 This Form is Open to Public Inspection
---	---	---

Part I	Annual Report Identification Information
For calendar plan year 2017 or fiscal plan year beginning <u>01/01/2017</u> and ending <u>05/01/2017</u>	
A	This return/report is for: ☐ a multiemployer plan ☒ a single-employer plan ☐ a multiple-employer plan (Filers checking this box must attach a list of participating employer information in accordance with the form instructions.) ☐ a DFE (specify) ____
B	This return/report is: ☐ the first return/report ☐ an amended return/report ☒ the final return/report ☒ a short plan year return/report (less than 12 months)
C	If the plan is a collectively-bargained plan, check here. ▶ ☐
D	Check box if filing under: ☒ Form 5558 ☐ special extension (enter description) ☐ automatic extension ☐ the DFVC program

Part II	Basic Plan Information —enter all requested information
1a	Name of plan <u>WIL RESEARCH LABORATORIES, LLC 401(K) PLAN</u>
1b	Three-digit plan number (PN) ▶ <u>001</u>
1c	Effective date of plan <u>01/01/2005</u>
2a	Plan sponsor's name (employer, if for a single-employer plan) Mailing address (include room, apt., suite no. and street, or P.O. Box) City or town, state or province, country, and ZIP or foreign postal code (if foreign, see instructions) <u>CHARLES RIVER LABORATORIES ASHLAND, LLC</u> <u>1407 GEORGE ROAD</u> <u>ASHLAND, OH 44805-8946</u>
2b	Employer Identification Number (EIN) <u>26-0564612</u>
2c	Plan Sponsor's telephone number <u>419-289-8700</u>
2d	Business code (see instructions) <u>541700</u>

Caution: A penalty for the late or incomplete filing of this return/report will be assessed unless reasonable cause is established.

Under penalties of perjury and other penalties set forth in the instructions, I declare that I have examined this return/report, including accompanying schedules, statements and attachments, as well as the electronic version of this return/report, and to the best of my knowledge and belief, it is true, correct, and complete.

SIGN HERE	Filed with authorized/valid electronic signature.	03/14/2018	MICHELLE HARTLEY
	Signature of plan administrator	Date	Enter name of individual signing as plan administrator
SIGN HERE	Filed with authorized/valid electronic signature.	03/14/2018	MICHELLE HARTLEY
	Signature of employer/plan sponsor	Date	Enter name of individual signing as employer or plan sponsor
SIGN HERE			
	Signature of DFE	Date	Enter name of individual signing as DFE

For Paperwork Reduction Act Notice, see the Instructions for Form 5500.

Form 5500 (2017)
v. 170203

3a Plan administrator's name and address ☒ Same as Plan Sponsor	3b Administrator's EIN 3c Administrator's telephone number
4 If the name and/or EIN of the plan sponsor or the plan name has changed since the last return/report filed for this plan, enter the plan sponsor's name, EIN, the plan name and the plan number from the last return/report: a Sponsor's name c Plan Name	4b EIN 4d PN
5 Total number of participants at the beginning of the plan year	5 1011
6 Number of participants as of the end of the plan year unless otherwise stated (welfare plans complete only lines 6a(1) , 6a(2) , 6b , 6c , and 6d).	
a(1) Total number of active participants at the beginning of the plan year	6a(1) 853
a(2) Total number of active participants at the end of the plan year	6a(2) 0
b Retired or separated participants receiving benefits	6b 0
c Other retired or separated participants entitled to future benefits	6c 0
d Subtotal. Add lines 6a(2) , 6b , and 6c	6d 0
e Deceased participants whose beneficiaries are receiving or are entitled to receive benefits.	6e 0
f Total. Add lines 6d and 6e	6f 0
g Number of participants with account balances as of the end of the plan year (only defined contribution plans complete this item)	6g 0
h Number of participants who terminated employment during the plan year with accrued benefits that were less than 100% vested	6h 0
7 Enter the total number of employers obligated to contribute to the plan (only multiemployer plans complete this item).....	7

8a If the plan provides pension benefits, enter the applicable pension feature codes from the List of Plan Characteristics Codes in the instructions:

2E 2F 2G 2J 2K 2T 3D

b If the plan provides welfare benefits, enter the applicable welfare feature codes from the List of Plan Characteristics Codes in the instructions:

9a Plan funding arrangement (check all that apply) (1) ☐ Insurance (2) ☐ Code section 412(e)(3) insurance contracts (3) ☒ Trust (4) ☐ General assets of the sponsor	9b Plan benefit arrangement (check all that apply) (1) ☐ Insurance (2) ☐ Code section 412(e)(3) insurance contracts (3) ☒ Trust (4) ☐ General assets of the sponsor
---	---

10 Check all applicable boxes in 10a and 10b to indicate which schedules are attached, and, where indicated, enter the number attached. (See instructions)

a Pension Schedules

- (1)** ☒ **R** (Retirement Plan Information)
- (2)** ☐ **MB** (Multiemployer Defined Benefit Plan and Certain Money Purchase Plan Actuarial Information) - signed by the plan actuary
- (3)** ☐ **SB** (Single-Employer Defined Benefit Plan Actuarial Information) - signed by the plan actuary

b General Schedules

- (1)** ☒ **H** (Financial Information)
- (2)** ☐ **I** (Financial Information – Small Plan)
- (3)** ☐ **A** (Insurance Information)
- (4)** ☒ **C** (Service Provider Information)
- (5)** ☒ **D** (DFE/Participating Plan Information)
- (6)** ☐ **G** (Financial Transaction Schedules)

Part III Form M-1 Compliance Information (to be completed by welfare benefit plans)

11a If the plan provides welfare benefits, was the plan subject to the Form M-1 filing requirements during the plan year? (See instructions and 29 CFR 2520.101-2.) ☐ Yes ☐ No

If "Yes" is checked, complete lines 11b and 11c.

11b Is the plan currently in compliance with the Form M-1 filing requirements? (See instructions and 29 CFR 2520.101-2.) ☐ Yes ☐ No

11c Enter the Receipt Confirmation Code for the 2017 Form M-1 annual report. If the plan was not required to file the 2017 Form M-1 annual report, enter the Receipt Confirmation Code for the most recent Form M-1 that was required to be filed under the Form M-1 filing requirements. (Failure to enter a valid Receipt Confirmation Code will subject the Form 5500 filing to rejection as incomplete.)

Receipt Confirmation Code _____

SCHEDULE C (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Service Provider Information This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA). ▶ File as an attachment to Form 5500.	OMB No. 1210-0110
		2017
		This Form is Open to Public Inspection.

For calendar plan year 2017 or fiscal plan year beginning 01/01/2017 and ending 05/01/2017		
A Name of plan WIL RESEARCH LABORATORIES, LLC 401(K) PLAN	B Three-digit plan number (PN) ▶	001
C Plan sponsor's name as shown on line 2a of Form 5500 CHARLES RIVER LABORATORIES ASHLAND, LLC	D Employer Identification Number (EIN) 26-0564612	

Part I	Service Provider Information (see instructions)
--------	---

You must complete this Part, in accordance with the instructions, to report the information required for **each person** who received, directly or indirectly, \$5,000 or more in total compensation (i.e., money or anything else of monetary value) in connection with services rendered to the plan or the person's position with the plan during the plan year. If a person received **only** eligible indirect compensation for which the plan received the required disclosures, you are required to answer line 1 but are not required to include that person when completing the remainder of this Part.

1 Information on Persons Receiving Only Eligible Indirect Compensation

a Check "Yes" or "No" to indicate whether you are excluding a person from the remainder of this Part because they received only eligible indirect compensation for which the plan received the required disclosures (see instructions for definitions and conditions).. ☒ Yes ☐ No

b If you answered line 1a "Yes," enter the name and EIN or address of each person providing the required disclosures for the service providers who received only eligible indirect compensation. Complete as many entries as needed (see instructions).

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation
AMERICAN BEACON
75-2401150

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation
BLACKROCK
04-6171663

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation
COLUMBIA
93-0577450

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation
FRANKLIN TEMPLETON INVESTMENTS
94-3167260

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

GOLDMAN SACHS

13-5108880

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

JANUS

43-1804048

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

JPMORGAN

13-2624428

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

MAINSTAY

52-2206685

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

METROPOLITAN WEST FUNDS

95-4597302

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

OAKMARK

04-3276558

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

OPPENHEIMER FUNDS

13-2527171

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

PIMCO FUNDS

95-2632339

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

PUTNAM

36-4488942

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

T. ROWE PRICE

52-2264646

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

2. Information on Other Service Providers Receiving Direct or Indirect Compensation. Except for those persons for whom you answered "Yes" to line 1a above, complete as many entries as needed to list each person receiving, directly or indirectly, \$5,000 or more in total compensation (i.e., money or anything else of value) in connection with services rendered to the plan or their position with the plan during the plan year. (See instructions).

(a) Enter name and EIN or address (see instructions)

WELLS FARGO BANK, N.A.

94-1347393

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
15 21 37 50 62 64	SERVICE PROVIDER	71641	Yes ☒ No ☐	Yes ☒ No ☐	0	Yes ☐ No ☒

(a) Enter name and EIN or address (see instructions)

MORGAN STANLEY GLOBAL BANKING OPERA

20-8764829

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
27 50	NONE	10000	Yes ☐ No ☒	Yes ☐ No ☐		Yes ☐ No ☐

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes ☐ No ☐	Yes ☐ No ☐		Yes ☐ No ☐

2. Information on Other Service Providers Receiving Direct or Indirect Compensation. Except for those persons for whom you answered "Yes" to line 1a above, complete as many entries as needed to list each person receiving, directly or indirectly, \$5,000 or more in total compensation (i.e., money or anything else of value) in connection with services rendered to the plan or their position with the plan during the plan year. (See instructions).

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes ☐ No ☐	Yes ☐ No ☐		Yes ☐ No ☐

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes ☐ No ☐	Yes ☐ No ☐		Yes ☐ No ☐

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes ☐ No ☐	Yes ☐ No ☐		Yes ☐ No ☐

Part I Service Provider Information (continued)

3. If you reported on line 2 receipt of indirect compensation, other than eligible indirect compensation, by a service provider, and the service provider is a fiduciary or provides contract administrator, consulting, custodial, investment advisory, investment management, broker, or recordkeeping services, answer the following questions for (a) each source from whom the service provider received \$1,000 or more in indirect compensation and (b) each source for whom the service provider gave you a formula used to determine the indirect compensation instead of an amount or estimated amount of the indirect compensation. Complete as many entries as needed to report the required information for each source.

(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	
(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	
(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	

Part II Service Providers Who Fail or Refuse to Provide Information

4 Provide, to the extent possible, the following information for each service provider who failed or refused to provide the information necessary to complete this Schedule.

(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide

Part III Termination Information on Accountants and Enrolled Actuaries (see instructions)
(complete as many entries as needed)

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

SCHEDULE D (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration		DFE/Participating Plan Information This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA). ▶ File as an attachment to Form 5500.		OMB No. 1210-0110 2017 This Form is Open to Public Inspection.	
For calendar plan year 2017 or fiscal plan year beginning 01/01/2017 and ending 05/01/2017					
A Name of plan WIL RESEARCH LABORATORIES, LLC 401(K) PLAN				B Three-digit plan number (PN) ▶ 001	
C Plan or DFE sponsor's name as shown on line 2a of Form 5500 CHARLES RIVER LABORATORIES ASHLAND, LLC				D Employer Identification Number (EIN) 26-0564612	
Part I Information on interests in MTIAs, CCTs, PSAs, and 103-12 IEs (to be completed by plans and DFEs) (Complete as many entries as needed to report all interests in DFEs)					
a Name of MTIA, CCT, PSA, or 103-12 IE: WELLS FARGO STABLE RETURN FUND N					
b Name of sponsor of entity listed in (a): WELLS FARGO BANK, N.A.					
c EIN-PN 41-6202499-001		d Entity code C		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 0	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
a Name of MTIA, CCT, PSA, or 103-12 IE:					
b Name of sponsor of entity listed in (a):					
c EIN-PN		d Entity code		e Dollar value of interest in MTIA,	

a Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)

Part II Information on Participating Plans (to be completed by DFEs)

(Complete as many entries as needed to report all participating plans)

a Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN

SCHEDULE H (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Financial Information This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA), and section 6058(a) of the Internal Revenue Code (the Code). ► File as an attachment to Form 5500.	OMB No. 1210-0110 2017 This Form is Open to Public Inspection
For calendar plan year 2017 or fiscal plan year beginning <u>01/01/2017</u> and ending <u>05/01/2017</u>		
A Name of plan <u>WIL RESEARCH LABORATORIES, LLC 401(K) PLAN</u>	B Three-digit plan number (PN) ►	<u>001</u>
C Plan sponsor's name as shown on line 2a of Form 5500 <u>CHARLES RIVER LABORATORIES ASHLAND, LLC</u>	D Employer Identification Number (EIN) <u>26-0564612</u>	

Part I	Asset and Liability Statement		(a) Beginning of Year	(b) End of Year
1 Current value of plan assets and liabilities at the beginning and end of the plan year. Combine the value of plan assets held in more than one trust. Report the value of the plan's interest in a commingled fund containing the assets of more than one plan on a line-by-line basis unless the value is reportable on lines 1c(9) through 1c(14). Do not enter the value of that portion of an insurance contract which guarantees, during this plan year, to pay a specific dollar benefit at a future date. Round off amounts to the nearest dollar. MTIAs, CCTs, PSAs, and 103-12 IEs do not complete lines 1b(1), 1b(2), 1c(8), 1g, 1h, and 1i. CCTs, PSAs, and 103-12 IEs also do not complete lines 1d and 1e. See instructions.				
	Assets			
a	Total noninterest-bearing cash	1a	128	
b	Receivables (less allowance for doubtful accounts):			
	(1) Employer contributions	1b(1)		
	(2) Participant contributions	1b(2)		
	(3) Other.....	1b(3)		
c	General investments:			
	(1) Interest-bearing cash (include money market accounts & certificates of deposit)	1c(1)		
	(2) U.S. Government securities.....	1c(2)		
	(3) Corporate debt instruments (other than employer securities):			
	(A) Preferred	1c(3)(A)		
	(B) All other.....	1c(3)(B)		
	(4) Corporate stocks (other than employer securities):			
	(A) Preferred	1c(4)(A)		
	(B) Common	1c(4)(B)		
	(5) Partnership/joint venture interests	1c(5)		
	(6) Real estate (other than employer real property)	1c(6)		
	(7) Loans (other than to participants)	1c(7)		
	(8) Participant loans	1c(8)	985617	0
	(9) Value of interest in common/collective trusts.....	1c(9)	1338226	0
	(10) Value of interest in pooled separate accounts.....	1c(10)		
	(11) Value of interest in master trust investment accounts	1c(11)		
	(12) Value of interest in 103-12 investment entities	1c(12)		
	(13) Value of interest in registered investment companies (e.g., mutual funds).....	1c(13)	44010280	0
	(14) Value of funds held in insurance company general account (unallocated contracts).....	1c(14)		
	(15) Other	1c(15)		

1d Employer-related investments:		(a) Beginning of Year	(b) End of Year
(1) Employer securities	1d(1)		
(2) Employer real property	1d(2)		
e Buildings and other property used in plan operation	1e		
f Total assets (add all amounts in lines 1a through 1e)	1f	46334251	0

Liabilities

g Benefit claims payable	1g		
h Operating payables	1h		
i Acquisition indebtedness	1i		
j Other liabilities	1j	0	
k Total liabilities (add all amounts in lines 1g through 1j)	1k	0	0

Net Assets

l Net assets (subtract line 1k from line 1f)	1l	46334251	0
---	-----------	----------	---

Part II Income and Expense Statement

- 2** Plan income, expenses, and changes in net assets for the year. Include all income and expenses of the plan, including any trust(s) or separately maintained fund(s) and any payments/receipts to/from insurance carriers. Round off amounts to the nearest dollar. MTIAs, CCTs, PSAs, and 103-12 IEs do not complete lines 2a, 2b(1)(E), 2e, 2f, and 2g.

Income

		(a) Amount	(b) Total
a Contributions:			
(1) Received or receivable in cash from: (A) Employers	2a(1)(A)	556150	
(B) Participants	2a(1)(B)	1135487	
(C) Others (including rollovers)	2a(1)(C)	29945	
(2) Noncash contributions	2a(2)		
(3) Total contributions. Add lines 2a(1)(A) , (B) , (C) , and line 2a(2)	2a(3)		1721582
b Earnings on investments:			
(1) Interest:			
(A) Interest-bearing cash (including money market accounts and certificates of deposit)	2b(1)(A)		
(B) U.S. Government securities	2b(1)(B)		
(C) Corporate debt instruments	2b(1)(C)		
(D) Loans (other than to participants)	2b(1)(D)		
(E) Participant loans	2b(1)(E)	10341	
(F) Other	2b(1)(F)		
(G) Total interest. Add lines 2b(1)(A) through (F)	2b(1)(G)		10341
(2) Dividends: (A) Preferred stock	2b(2)(A)		
(B) Common stock	2b(2)(B)		
(C) Registered investment company shares (e.g. mutual funds)	2b(2)(C)	86582	
(D) Total dividends. Add lines 2b(2)(A) , (B) , and (C)	2b(2)(D)		86582
(3) Rents	2b(3)		
(4) Net gain (loss) on sale of assets: (A) Aggregate proceeds	2b(4)(A)		
(B) Aggregate carrying amount (see instructions)	2b(4)(B)		
(C) Subtract line 2b(4)(B) from line 2b(4)(A) and enter result	2b(4)(C)		0
(5) Unrealized appreciation (depreciation) of assets: (A) Real estate	2b(5)(A)		
(B) Other	2b(5)(B)		
(C) Total unrealized appreciation of assets. Add lines 2b(5)(A) and (B)	2b(5)(C)		0

		(a) Amount	(b) Total
(6) Net investment gain (loss) from common/collective trusts	2b(6)		0
(7) Net investment gain (loss) from pooled separate accounts	2b(7)		
(8) Net investment gain (loss) from master trust investment accounts	2b(8)		
(9) Net investment gain (loss) from 103-12 investment entities	2b(9)		
(10) Net investment gain (loss) from registered investment companies (e.g., mutual funds).....	2b(10)		2851457
c Other income	2c		0
d Total income. Add all income amounts in column (b) and enter total.....	2d		4669962

Expenses

e Benefit payment and payments to provide benefits:			
(1) Directly to participants or beneficiaries, including direct rollovers.....	2e(1)	1254592	
(2) To insurance carriers for the provision of benefits	2e(2)		
(3) Other	2e(3)		
(4) Total benefit payments. Add lines 2e(1) through (3).....	2e(4)		1254592
f Corrective distributions (see instructions)	2f		0
g Certain deemed distributions of participant loans (see instructions).....	2g		
h Interest expense.....	2h		
i Administrative expenses: (1) Professional fees	2i(1)		
(2) Contract administrator fees	2i(2)		
(3) Investment advisory and management fees	2i(3)		
(4) Other	2i(4)	82466	
(5) Total administrative expenses. Add lines 2i(1) through (4).....	2i(5)		82466
j Total expenses. Add all expense amounts in column (b) and enter total.....	2j		1337058

Net Income and Reconciliation

k Net income (loss). Subtract line 2j from line 2d	2k		3332904
l Transfers of assets:			
(1) To this plan.....	2l(1)		
(2) From this plan	2l(2)		49667155

Part III Accountant's Opinion

3 Complete lines 3a through 3c if the opinion of an independent qualified public accountant is attached to this Form 5500. Complete line 3d if an opinion is not attached.

a The attached opinion of an independent qualified public accountant for this plan is (see instructions):

(1) ☐ Unqualified (2) ☐ Qualified (3) ☒ Disclaimer (4) ☐ Adverse

b Did the accountant perform a limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)?

☒ Yes ☐ No

c Enter the name and EIN of the accountant (or accounting firm) below:

(1) Name: DG KRAUSE LLC

(2) EIN: 20-2621108

d The opinion of an independent qualified public accountant is **not attached** because:

(1) ☐ This form is filed for a CCT, PSA, or MTIA. (2) ☐ It will be attached to the next Form 5500 pursuant to 29 CFR 2520.104-50.

Part IV Compliance Questions

4 CCTs and PSAs do not complete Part IV. MTIAs, 103-12 IEs, and GIAs do not complete lines 4a, 4e, 4f, 4g, 4h, 4k, 4m, 4n, or 5. 103-12 IEs also do not complete lines 4j and 4l. MTIAs also do not complete line 4l.

During the plan year:

a Was there a failure to transmit to the plan any participant contributions within the time period described in 29 CFR 2510.3-102? Continue to answer "Yes" for any prior year failures until fully corrected. (See instructions and DOL's Voluntary Fiduciary Correction Program.).....

b Were any loans by the plan or fixed income obligations due the plan in default as of the close of the plan year or classified during the year as uncollectible? Disregard participant loans secured by participant's account balance. (Attach Schedule G (Form 5500) Part I if "Yes" is checked.)

	Yes	No	Amount
4a		X	
4b		X	

		Yes	No	Amount
c Were any leases to which the plan was a party in default or classified during the year as uncollectible? (Attach Schedule G (Form 5500) Part II if "Yes" is checked.)	4c		X	
d Were there any nonexempt transactions with any party-in-interest? (Do not include transactions reported on line 4a. Attach Schedule G (Form 5500) Part III if "Yes" is checked.)	4d		X	
e Was this plan covered by a fidelity bond?	4e	X		1000000
f Did the plan have a loss, whether or not reimbursed by the plan's fidelity bond, that was caused by fraud or dishonesty?	4f		X	
g Did the plan hold any assets whose current value was neither readily determinable on an established market nor set by an independent third party appraiser?	4g		X	
h Did the plan receive any noncash contributions whose value was neither readily determinable on an established market nor set by an independent third party appraiser?	4h		X	
i Did the plan have assets held for investment? (Attach schedule(s) of assets if "Yes" is checked, and see instructions for format requirements.)	4i		X	
j Were any plan transactions or series of transactions in excess of 5% of the current value of plan assets? (Attach schedule of transactions if "Yes" is checked, and see instructions for format requirements.)	4j		X	
k Were all the plan assets either distributed to participants or beneficiaries, transferred to another plan, or brought under the control of the PBGC?	4k	X		
l Has the plan failed to provide any benefit when due under the plan?	4l		X	
m If this is an individual account plan, was there a blackout period? (See instructions and 29 CFR 2520.101-3.)	4m	X		
n If 4m was answered "Yes," check the "Yes" box if you either provided the required notice or one of the exceptions to providing the notice applied under 29 CFR 2520.101-3.	4n	X		

5a Has a resolution to terminate the plan been adopted during the plan year or any prior plan year? ☐ Yes ☒ No
 If "Yes," enter the amount of any plan assets that reverted to the employer this year 0.

5b If, during this plan year, any assets or liabilities were transferred from this plan to another plan(s), identify the plan(s) to which assets or liabilities were transferred. (See instructions.)

5b(1) Name of plan(s)	5b(2) EIN(s)	5b(3) PN(s)
QS PHARMA LLC 401(K) PLAN	04-3599000	001
CHARLES RIVER LABORATORIES, INC. SAVINGS/PLUS PLAN	76-0509980	004

5c If the plan is a defined benefit plan, is it covered under the PBGC insurance program (See ERISA section 4021.)? ☐ Yes ☐ No ☐ Not determined
 If "Yes" is checked, enter the My PAA confirmation number from the PBGC premium filing for this plan year _____ . (See instructions.)

SCHEDULE R (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Retirement Plan Information This schedule is required to be filed under sections 104 and 4065 of the Employee Retirement Income Security Act of 1974 (ERISA) and section 6058(a) of the Internal Revenue Code (the Code). ▶ File as an attachment to Form 5500.	OMB No. 1210-0110 2017 This Form is Open to Public Inspection.
---	---	--

For calendar plan year 2017 or fiscal plan year beginning 01/01/2017 and ending 05/01/2017

A Name of plan <u>WIL RESEARCH LABORATORIES, LLC 401(K) PLAN</u>	B Three-digit plan number (PN) ▶ <u>001</u>
C Plan sponsor's name as shown on line 2a of Form 5500 <u>CHARLES RIVER LABORATORIES ASHLAND, LLC</u>	D Employer Identification Number (EIN) <u>26-0564612</u>

Part I	Distributions
---------------	----------------------

All references to distributions relate only to payments of benefits during the plan year.

1 Total value of distributions paid in property other than in cash or the forms of property specified in the instructions	1	<u>0</u>
2 Enter the EIN(s) of payor(s) who paid benefits on behalf of the plan to participants or beneficiaries during the year (if more than two, enter EINs of the two payors who paid the greatest dollar amounts of benefits): EIN(s): <u>41-6257133</u>		
Profit-sharing plans, ESOPs, and stock bonus plans, skip line 3.		
3 Number of participants (living or deceased) whose benefits were distributed in a single sum, during the plan year	3	

Part II	Funding Information (If the plan is not subject to the minimum funding requirements of section 412 of the Internal Revenue Code or ERISA section 302, skip this Part.)
----------------	---

4 Is the plan administrator making an election under Code section 412(d)(2) or ERISA section 302(d)(2)?	☐ Yes	☐ No	☐ N/A
If the plan is a defined benefit plan, go to line 8.			
5 If a waiver of the minimum funding standard for a prior year is being amortized in this plan year, see instructions and enter the date of the ruling letter granting the waiver. Date: Month _____ Day _____ Year _____ If you completed line 5, complete lines 3, 9, and 10 of Schedule MB and do not complete the remainder of this schedule.			
6 a Enter the minimum required contribution for this plan year (include any prior year accumulated funding deficiency not waived)	6a		
b Enter the amount contributed by the employer to the plan for this plan year	6b		
c Subtract the amount in line 6b from the amount in line 6a. Enter the result (enter a minus sign to the left of a negative amount)	6c		
If you completed line 6c, skip lines 8 and 9.			
7 Will the minimum funding amount reported on line 6c be met by the funding deadline?	☐ Yes	☐ No	☐ N/A
8 If a change in actuarial cost method was made for this plan year pursuant to a revenue procedure or other authority providing automatic approval for the change or a class ruling letter, does the plan sponsor or plan administrator agree with the change?	☐ Yes	☐ No	☐ N/A

Part III	Amendments
-----------------	-------------------

9 If this is a defined benefit pension plan, were any amendments adopted during this plan year that increased or decreased the value of benefits? If yes, check the appropriate box. If no, check the "No" box.	☐ Increase	☐ Decrease	☐ Both	☐ No
---	-----------------------------------	-----------------------------------	-------------------------------	-----------------------------

Part IV	ESOPs (see instructions). If this is not a plan described under section 409(a) or 4975(e)(7) of the Internal Revenue Code, skip this Part.
----------------	---

10 Were unallocated employer securities or proceeds from the sale of unallocated securities used to repay any exempt loan?	☐ Yes	☐ No
11 a Does the ESOP hold any preferred stock?	☐ Yes	☐ No
b If the ESOP has an outstanding exempt loan with the employer as lender, is such loan part of a "back-to-back" loan? (See instructions for definition of "back-to-back" loan.)	☐ Yes	☐ No
12 Does the ESOP hold any stock that is not readily tradable on an established securities market?	☐ Yes	☐ No

For Paperwork Reduction Act Notice, see the Instructions for Form 5500.

Schedule R (Form 5500) 2017
v. 170203

Part V Additional Information for Multiemployer Defined Benefit Pension Plans

13 Enter the following information for each employer that contributed more than 5% of total contributions to the plan during the plan year (measured in dollars). See instructions. *Complete as many entries as needed to report all applicable employers.*

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

- 14** Enter the number of participants on whose behalf no contributions were made by an employer as an employer of the participant for:

a The current year	14a	
b The plan year immediately preceding the current plan year	14b	
c The second preceding plan year	14c	

- 15** Enter the ratio of the number of participants under the plan on whose behalf no employer had an obligation to make an employer contribution during the current plan year to:

a The corresponding number for the plan year immediately preceding the current plan year	15a	
b The corresponding number for the second preceding plan year	15b	

- 16** Information with respect to any employers who withdrew from the plan during the preceding plan year:

a Enter the number of employers who withdrew during the preceding plan year	16a	
b If line 16a is greater than 0, enter the aggregate amount of withdrawal liability assessed or estimated to be assessed against such withdrawn employers	16b	

- 17** If assets and liabilities from another plan have been transferred to or merged with this plan during the plan year, check box and see instructions regarding supplemental information to be included as an attachment. ☐

Part VI Additional Information for Single-Employer and Multiemployer Defined Benefit Pension Plans

- 18** If any liabilities to participants or their beneficiaries under the plan as of the end of the plan year consist (in whole or in part) of liabilities to such participants and beneficiaries under two or more pension plans as of immediately before such plan year, check box and see instructions regarding supplemental information to be included as an attachment ☐

- 19** If the total number of participants is 1,000 or more, complete lines (a) through (c)

- a** Enter the percentage of plan assets held as:
 Stock: _____% Investment-Grade Debt: _____% High-Yield Debt: _____% Real Estate: _____% Other: _____%
- b** Provide the average duration of the combined investment-grade and high-yield debt:
☐ 0-3 years ☐ 3-6 years ☐ 6-9 years ☐ 9-12 years ☐ 12-15 years ☐ 15-18 years ☐ 18-21 years ☐ 21 years or more
- c** What duration measure was used to calculate line 19(b)?
☐ Effective duration ☐ Macaulay duration ☐ Modified duration ☐ Other (specify): _____

Financial Statements and Supplemental Schedules

WIL Research Laboratories, LLC
401(k) Plan

*May 1, 2017 and December 31, 2016 and 2015 and for the period from January 1, 2017 through
May 1, 2017 and for the year ended December 31, 2016 with Independent Auditor's Report*

WIL Research Laboratories, LLC
401(k) Plan

Financial Statements and Supplemental Schedules

May 1, 2017 and December 31, 2016 and 2015 and for the period January 1, 2017
through May 1, 2017 and for the year ended December 31, 2016

Contents

Independent Auditor's Report	1
------------------------------------	---

Financial Statements

Statements of Net Assets Available for Benefits	3
Statements of Changes in Net Assets Available for Benefits.....	4
Notes to Financial Statements	5

Supplemental Schedules

Schedule H, line 4a-Schedule of Delinquent Participant Contributions for the year ended December 31, 2016.....	17
Schedule H, line 4i-Schedule of Assets (Held At End of Year) December 31, 2016	18



DG Krause LLC
7862 Shady Woods Dr
Indianapolis, Indiana 46259

Phone: (317) 245-7932
www.dgkllc.com

Independent Auditor's Report

Plan Administrator of
WIL Research Laboratories, LLC 401(k) Plan

Report on the Financial Statements

We were engaged to audit the accompanying financial statements of the WIL Research Laboratories, LLC 401(k) Plan (the Plan), which comprise the statements of net assets available for benefits as of May 1, 2017 and December 31, 2016 and 2015, and the related statements of changes in net assets available for benefits for the period from January 1, 2017 through May 1, 2017 and for the year ended December 31, 2016, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on conducting the audit in accordance with auditing standards generally accepted in the United States of America. Because of the matter described in the Basis for Disclaimer of Opinion paragraph, however, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion.

Basis for Disclaimer of Opinion

As permitted by 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974, the plan administrator instructed us not to perform, and we did not perform, any auditing procedures with respect to the information summarized in Note 3, which was certified by Wells Fargo Bank, N.A., the trustee of the Plan, except for comparing such information with the related information included in the financial statements. We have been informed by the plan administrator that the trustee holds the Plan's investment assets and executes investment transactions. The plan administrator has obtained a certification from the trustee as of May 1, 2017 and December 31, 2016 and 2015, and for period from January 1, 2017

through May 1, 2017 and for the year ended December 31, 2016, that the information provided to the plan administrator by the trustee is complete and accurate.

Disclaimer of Opinion

Because of the significance of the matter described in the Basis for Disclaimer of Opinion paragraph, we have not been able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion. Accordingly, we do not express an opinion on these financial statements.

Emphasis of Matter Relating to Plan Merger

The Plan merged into the Charles River Laboratories, Inc. Savings/Plus Plan effective May 1, 2017. See Note 1.

Other Matter Supplemental Schedules

The supplemental Schedule H, line 4a – Schedule of Delinquent Participant Contributions for the year ended December 31, 2016 and Schedule H, line 4i – Schedule of Assets (Held At End of Year) as of December 31, 2016, are required by the Department of Labor's (DOL) Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974 and are presented for the purpose of additional analysis and are not a required part of the financial statements. Because of the significance of the matter described in the Basis for Disclaimer of Opinion paragraph, we do not express an opinion on the supplemental schedules.

Report on Form and Content in Compliance with DOL Rules and Regulations

The form and content of the information included in the financial statements and supplemental schedules, other than that derived from the information certified by the trustee, have been audited by us in accordance with auditing standards generally accepted in the United States of America and, in our opinion, are presented in compliance with the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974.



Indianapolis, Indiana
March 14, 2018

WIL Research Laboratories, LLC
401(k) Plan

Statements of Net Assets Available for Benefits

	May 1	December 31	
	2017	2016	2015
Assets			
Investments, at fair value	\$ -	\$ 45,348,506	\$ 38,520,842
Cash	-	128	631
Contributions receivable from participants	-	-	550
Contributions receivable from employer	-	-	1,147
Other receivable	-	-	3,478
Notes receivable from participants	-	985,617	1,072,948
Total assets	-	46,334,251	39,599,596
Liabilities			
Excess contributions refundable	-	-	923
Accrued administrative expenses	-	28,832	25,169
Total liabilities	-	28,832	26,092
Net assets available for benefits	\$ -	\$46,305,419	\$39,573,504

See accompanying notes to financial statements.

WIL Research Laboratories, LLC
401(k) Plan

Statements of Changes in Net Assets Available for Benefits

	Period from January 1, 2017 through May 1, 2017	Year ended December 31, 2016
Additions:		
Contributions:		
Participants	\$ 1,135,487	\$ 3,829,767
Rollovers	29,945	187,172
Employer	556,150	1,953,021
	<u>1,721,582</u>	<u>5,969,960</u>
Net realized and unrealized appreciation in fair value of investments	2,851,457	3,423,495
Investment income	86,582	648,848
Interest income on notes receivable from participants	10,341	41,660
Total additions	<u>4,669,962</u>	<u>10,083,963</u>
Deductions:		
Benefits paid	(1,254,592)	(3,182,299)
Administrative expenses	(53,634)	(169,749)
Total deductions	<u>(1,308,226)</u>	<u>(3,352,048)</u>
Net increase	3,361,736	6,731,915
Transfers to other plans	(49,667,155)	-
Net assets available for benefits at beginning of year	<u>46,305,419</u>	<u>39,573,504</u>
Net assets available for benefits at end of year	<u>\$ -</u>	<u>\$ 46,305,419</u>

See accompanying notes to financial statements.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements

May 1, 2017 and December 31, 2016

1. Description of the Merged Plan

The following brief description of the WIL Research Laboratories, LLC 401(k) Plan (the Plan) is provided for general information purposes only. Participants should refer to the Summary Plan Description for more complete information.

Current Developments

On April 4, 2016 Charles River Laboratories, International, Inc. acquired WIL Research Laboratories, LLC and the other related entities that participate in the Plan.

On April 27, 2016 the Plan Sponsor provided written notice to Wells Fargo Bank, N.A. of its desire to redeem the Plan's investment in the Wells Fargo Stable Return Fund N. The fund has a 12 month redemption notice period, unless waived. In April 2017, following the redemption notice period, the investment in the fund was redeemed at its net asset value (NAV), with no reduction in value incurred by the Plan.

On June 24, 2016 the legal names of the following entities that participate in the Plan were changed as indicated below:

Former legal name	New legal name
WIL Research Laboratories, LLC	Charles River Laboratories Ashland, LLC
WIL Research-Skokie, LLC	Charles River Laboratories Skokie, LLC
QS Pharma, LLC	Charles River Laboratories Contract Manufacturing PA, LLC
WIL Research –Hillsborough, LLC	Charles River Laboratories Hillsborough, LLC
WIL Research Company, Inc.	Charles River Laboratories SA USA, Inc.

Effective December 31, 2016, Charles River Laboratories Hillsborough, LLC ceased to be a participating employer in the Plan. Effective April 2, 2017 Charles River Laboratories Skokie, LLC merged into Charles River Laboratories Ashland, LLC.

Plan Freeze

Effective April 1, 2017 the Plan was amended to freeze the Plan. All contributions to the Plan were ceased. Participants remained fully vested in their accounts within the Plan. Also, effective April 1, 2017 certain participants of the Plan became eligible to participate in the Charles River Laboratories, Inc. Savings/Plus Plan.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements

May 1, 2017 and December 31, 2016

1. Description of the Merged Plan (continued)

Plan Spin-off

Effective February 9, 2017, Charles River Laboratories Contract Manufacturing PA, LLC was sold to an independent third party. Concurrent with the sale, Charles River Laboratories Contract Manufacturing PA, LLC ceased to be a participating employer in the Plan. Effective April 1, 2017, Charles River Laboratories SA USA, Inc. also ceased to be a participating employer in the Plan.

Following the transaction to sell the entity described above, effective May 1, 2017 the individual participant accounts of the Plan for certain participants, who had been employed by Charles River Laboratories Contract Manufacturing PA, LLC, were spun-off to a newly formed ERISA plan named QS Pharma LLC 401(k) Plan. As a result of this spin-off, investments of \$4,135,210 and notes receivable from participants of \$68,261 were transferred from the Plan to the QS Pharma LLC 401(k) Plan on May 1, 2017. The QS Pharma LLC 401(k) Plan was subsequently renamed Quotient Sciences – Philadelphia, LLC 401(k) Plan through a plan amendment effective December 31, 2017.

Plan Merger

Effective May 1, 2017, the Plan merged into the Charles River Laboratories, Inc. Savings/Plus Plan. As a result of this plan merger, investments of \$44,526,205 and notes receivable from participants of \$937,479 were transferred from the Plan to the Charles River Laboratories, Inc. Savings/Plus Plan on May 1, 2017. Following this transaction the Plan had no remaining net assets available for benefits.

General

The Plan was established January 1, 2005. The Plan is a voluntary defined contribution plan covering all employees (except employees represented by a bargaining unit, non-resident aliens, leased employees, and independent contractors or their employees who are later determined by the IRS to be an employee) of Charles River Laboratories Ashland, LLC (Company). For the year ended December 31, 2016, employees of Charles River Laboratories Skokie, LLC, Charles River Laboratories Contract Manufacturing PA, LLC, Charles River Laboratories Hillsborough, LLC, and Charles River Laboratories SA USA Inc., members of the controlled group including Charles River Laboratories Ashland, LLC, were also eligible to participate in the Plan. Entry into the Plan is the first day of the Plan

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements

May 1, 2017 and December 31, 2016

1. Description of the Merged Plan (continued)

General (continued)

quarter following the date that eligibility requirements are satisfied. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA), as amended.

Contributions

Plan participants may contribute up to 100 percent of their pretax annual compensation, as defined in the Plan, subject to certain Internal Revenue Code limitations. The Company contributes 100 percent of the first 3 percent of pretax annual compensation that a participant contributes to the Plan, plus 50 percent of participant contributions which are over 3 percent of pay but not over 5 percent of pay. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans. The Plan includes an automatic deferral feature. Accordingly, 3% of eligible compensation will be automatically deferred for participants who do not elect an alternative deferral amount or elect not to defer. The automatic deferral amount will increase 1% on July 1 of each plan year, up to a maximum of 8%, unless the participant opts out of the automatic increase.

Effective July 1, 2014, for every participant deferring between 1% and 7% of eligible compensation, there was and will be an increase by 1% on the first day of July each Plan year until a maximum deferral percentage of 8% is reached. A participant who elects to opt out of the automatic increase shall not be subject to the annual increase in subsequent years.

Vesting

Participants are always 100% vested in their total account.

Participant Accounts and Investment Options

Individual accounts are maintained for each Plan participant. Each participant's account is credited with the participant's contribution, the Company's matching contribution, and Plan earnings, and charged with withdrawals and an allocation of Plan losses. Allocations are based on participant earnings or account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account. All amounts in participant accounts are participant-directed.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements

May 1, 2017 and December 31, 2016

1. Description of the Merged Plan (continued)

Notes Receivable from Participants

Participants may only have one loan outstanding from the Plan at a time and may borrow from their accounts a minimum of \$1,000 up to a maximum equal to the lesser of \$50,000 or 50% of their vested account balance, whichever is less. The loans are secured by the balance in the participant's account and bear interest at rates commensurate with local prevailing rates as determined quarterly by the Plan administrator. Principal and interest is paid ratably through payroll deductions.

Payment of Benefits

On termination of service due to death, disability, or retirement, the Plan provides for a lump-sum amount equal to the value of the participant's vested interest in his or her account. For termination of service for other reasons, a participant may receive the value of the vested interest in his or her account as a lump-sum distribution.

Unallocated Accounts

As of December 31, 2016 and 2015, approximately \$65,500 and \$138,500, respectively, of reported net assets available for benefits of the Plan, which have not been allocated to specific participant accounts, are temporarily maintained in an ERISA Account. These amounts, which have been reported as net appreciation in fair value of investments, originate through the rebating to the Plan by Wells Fargo Bank, N.A., the trustee, revenue sharing amounts it receives relating to the Plan's mutual fund investments. During the plan year ended December 31, 2016, approximately \$73,000 was credited to individual participant accounts from the ERISA Account. An unallocated amount of approximately \$50,700 was included in the amount of net assets transferred to the Charles River Laboratories, Inc. Savings/Plus Plan as part of the Plan merger and will be used in the future to pay expenses or be credited to individual participant accounts through earnings allocations.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

2. Summary of Significant Accounting Policies

Use of Estimates and Basis of Accounting

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires Plan management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.

The financial statements of the Plan are prepared on the accrual basis of accounting.

Investment Valuation and Income Recognition

The Plan's investments are stated at fair value. Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. See Note 4 for discussion of fair value measurements.

Notes Receivable from Participants

Notes receivable from participants are measured and reported at unpaid principal balance plus accrued but unpaid interest. Delinquent notes receivable from participants are recorded as a distribution based upon the terms of the plan document.

Risks and Uncertainties

The Plan invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the value of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the statements of net assets available for benefits.

Expenses of the Plan

Certain expenses of administering the Plan and the related Plan assets are paid by the Company. Participants are charged fees for certain participant initiated transactions.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Payment of Benefits

Benefit payments to participants are recorded upon distribution.

Subsequent Events

Subsequent events were evaluated through March 14, 2018, which is the date the financial statements were available to be issued.

3. Investments and Notes Receivable from Participants

All investment information disclosed in the accompanying financial statements and schedules, including investments at December 31, 2016 and 2015, notes receivable from participants at December 31, 2016 and 2015 and investment income, net appreciation in fair value of investments and interest income on notes receivable from participants for the period January 1, 2017 through May 1, 2017 and for the year ended December 31, 2016, was obtained or derived from information supplied to the Plan administrator and certified as complete and accurate by Wells Fargo Bank, N.A., the trustee of the Plan.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

4. Fair Value Measurements

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3). The three levels of the fair value hierarchy under Topic 820 are described as follows:

Level 1	Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
Level 2	Inputs to the valuation methodology include • quoted prices for similar assets or liabilities in active markets; • quoted prices for identical or similar assets or liabilities in inactive markets; • inputs other than quoted prices that are observable for the asset or liability; • inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.
Level 3	Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at December 31, 2016 and 2015. There were no assets held as of May 1, 2017 following the merger of the Plan disclosed in Note 1.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

4. Fair Value Measurements (continued)

The mutual funds are valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the U.S. Securities and Exchange Commission. These funds are required to publish their daily net asset value and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

The stable value collective trust fund is composed primarily of fully benefit-responsive investment contracts that is valued at the net asset value of units of the bank collective trust. The net asset value is used as a practical expedient to estimate fair value. This practical expedient would not be used if it is determined to be probable that the fund will sell the investment for an amount different from the reported net asset value. Participant transactions (purchases and sales) may occur daily. If the Plan initiates a full redemption of the collective trust, the issuer reserves the right to require 12 months' notification to ensure that security liquidations will be carried out in an orderly business manner. See Note 1.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

4. Fair Value Measurements (continued)

The following table sets forth by level, within the fair value hierarchy, the Plan's assets at fair value as of December 31, 2016:

	Level 1	Level 2	Level 3	Total
Mutual funds	\$44,010,280	\$ -	\$ -	\$ 44,010,280
Investments measured at net asset value (a)	-	-	-	1,338,226
Investments at fair value	\$44,010,280	\$ -	\$ -	\$ 45,348,506

The following table sets forth by level, within the fair value hierarchy, the Plan's assets at fair value as of December 31, 2015:

	Level 1	Level 2	Level 3	Total
Mutual funds	\$37,097,050	\$ -	\$ -	\$ 37,097,050
Investments measured at net asset value (a)	-	-	-	1,423,792
Investments at fair value	\$37,097,050	\$ -	\$ -	\$ 38,520,842

(a) In accordance with Subtopic 820-10, certain investments that were measured at net asset value per share (or its equivalent) have not been classified in the fair value hierarchy. The fair value amounts presented in this table for those investments are intended to permit reconciliation of the fair value of those assets classified in the hierarchy table to the line items presented in the statements of net assets available for benefits.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

4. Fair Value Measurements (continued)

Fair Value of Investments in Entities that Use Net Asset Value

The following table summarizes investments measured at fair value based on net asset value (NAVs) per share as of December 31, 2016:

December 31, 2016	Fair Value	Unfunded Commitments	Redemption Frequency (if currently eligible)	Redemption Notice Period
Collective trust fund – Wells Fargo Stable Return Fund N	\$1,338,226	n/a	Daily	12 months written notice, which at the discretion of Wells Fargo may be waived. See Note 1.

The following table summarizes investments measured at fair value based on net asset value (NAVs) per share as of December 31, 2015:

December 31, 2015	Fair Value	Unfunded Commitments	Redemption Frequency (if currently eligible)	Redemption Notice Period
Collective trust fund – Wells Fargo Stable Return Fund N	\$1,423,792	n/a	Daily	12 months written notice, which at the discretion of Wells Fargo may be waived

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

5. Income Tax Status

The Plan was restated effective January 1, 2016. The underlying volume submitter profit sharing plan with CODA, which was adopted with this plan restatement, has received an opinion letter from the IRS dated March 31, 2014 stating that the form of the plan is qualified under section 401 of the Code, and therefore the related trust is tax exempt. In accordance with Revenue Procedure 2011-49, 2011-44 I.R.B.608 the Company has determined that it is eligible to and has chosen to rely on the current IRS volume submitter opinion letter. Once qualified, the Plan is required to operate in conformity with the Code to maintain its qualification. The Plan Sponsor believes that they have operated and merged the Plan in a manner that has not jeopardized the qualified status of the Plan.

Accounting principles generally accepted in the United States of America require plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of May 1, 2017, there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

6. Plan Termination

The Company had the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions set forth in ERISA. See Note 1.

7. Transactions with Parties in Interest

The Plan invests in a collective trust fund and mutual fund sponsored by affiliates of the Plan's trustee, who is a party in interest. Such transactions represent statutorily exempt transactions.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

8. Reconciliation of Financial Statements to Form 5500

The following is a reconciliation of net assets available for benefits per the financial statements to the Form 5500:

	December 31 2016	December 31 2015
Net assets available for benefits per the financial statements	\$46,305,419	\$39,573,504
Less contributions receivable from employer	-	(1,147)
Less contributions receivable from participants	-	(550)
Less other receivable	-	(3,478)
Add accrued administrative expenses	28,832	25,169
Add excess contributions refundable	-	923
Net assets available for benefits per Form 5500	<u>\$46,334,251</u>	<u>\$39,594,421</u>

The following is a reconciliation of changes in net assets available for benefits per the financial statements to the Form 5500:

	Year Ended December 31 2016
Net increase in net assets available for benefits per the financial statements	\$ 6,731,915
Add net change in contributions receivable from employer	1,147
Add net change in contributions receivable from participants	550
Add net change in other receivable	3,478
Less net change in excess contributions refundable	(923)
Add net change in accrued administrative expenses	3,663
Net increase per the Form 5500	<u>\$ 6,739,830</u>

Certain differences result from the financial statements being prepared on the accrual basis of accounting and the Form 5500 being prepared on a modified cash basis. Accordingly, the net increase in net assets available for benefits, prior to transfers of assets from this Plan for the period from January 1, 2017 through May 1, 2017 was \$28,832 less for Form 5500 purposes than for financial statement purposes, as a result of the modified cash basis recognition of administrative expenses during the period for Form 5500 purposes.

Supplemental Schedules

WIL Research Laboratories, LLC 401(k) Plan

Schedule H, line 4a – Schedule of Delinquent Participant Contributions
Year ended December 31, 2016

EIN#: 26-0564612

Plan #: 001

Participant Contributions Transferred Late to Plan	Total that Constitute Nonexempt Prohibited Transactions			Total Fully Corrected under VFCP and PTE 2002-51
Check here if Late Participant Loan Repayments are included: ☒	Contributions Not Corrected	Contributions Corrected Outside VFCP	Contributions Pending Correction in VFCP	
\$ 10,621	\$ -	\$ 10,621	\$ -	\$ -

WIL Research Laboratories, LLC
401(k) Plan

Schedule H, line 4i–Schedule of Assets (Held At End of Year)

December 31, 2016

EIN #: 26-0564612

Plan #: 001

Identity of Issue, Borrower Lessor or Similar Party	Description of Investment Including Maturity Date, Rate of Interest, Par or Maturity Value	Current Value
Collective Trust Fund:		
*Wells Fargo Stable Return Fund N	25,111 Units	\$ 1,338,226
Mutual Funds:		
COLUMBIA LARGE CAP INDEX Z	79,005 Shares	3,385,380
JP MORGAN SMART RETIREMENT INCOME A	39,052 Shares	677,947
TEMPLETON GLOBAL BOND A	47,575 Shares	570,904
PUTNAM GROWTH OPPORTUNITIES Y	80,201 Shares	2,033,902
JP MORGAN SMART RETIREMENT 2015 A	1,970 Shares	34,250
JP MORGAN SMART RETIREMENT 2020 A	176,641 Shares	3,190,129
JP MORGAN SMART RETIREMENT 2025 A	38,595 Shares	675,413
JP MORGAN SMART RETIREMENT 2030 A	311,922 Shares	5,851,660
JP MORGAN SMART RETIREMENT 2035 A	26,257 Shares	472,108
JP MORGAN SMART RETIREMENT 2040 A	284,405 Shares	5,483,330
JP MORGAN SMART RETIREMENT 2045 A	34,011 Shares	621,379
JP MORGAN SMART RETIREMENT 2050 A	260,810 Shares	4,754,569
JP MORGAN SMART RETIREMENT 2055 A	32,095 Shares	651,208
COLUMBIA SMALL CAP INDEX Z	143,441 Shares	3,396,685
BLACKROCK HIGH YIELD PORTFOLIO A	50,660 Shares	386,539
AMERICAN BEACON SMALL CAP VALUE/ADVISOR	55,393 Shares	1,462,381
BLACKROCK EQUITY DIVIDEND A	90,574 Shares	2,037,915
JP MORGAN MID CAP GROWTH FUND A	47,205 Shares	1,144,721
METROPOLITAN WEST TOTAL RETURN BOND M	187,058 Shares	1,971,595
OPPENHEIMER DEVELOPING MKTS FUND A	9,250 Shares	299,886
*WELLS FARGO SPECIAL MID CAP VALUE A	58,470 Shares	2,056,382
OAKMARK INTERNATIONAL II	101,731 Shares	2,323,543
QM US SMALL CAP GROWTH EQUITY	18,477 Shares	528,454
		44,010,280
Participant Loans	Loans to Participants, \$985,617 principal amount and accrued interest, various maturity dates and each loan with a 4.25%-4.75% interest rate	985,617
		\$ 46,334,123

* Indicates a party-in-interest to the Plan.

Note: Cost data is not required to be presented for participant-directed investments.

Financial Statements and Supplemental Schedules

WIL Research Laboratories, LLC
401(k) Plan

*May 1, 2017 and December 31, 2016 and 2015 and for the period from January 1, 2017 through
May 1, 2017 and for the year ended December 31, 2016 with Independent Auditor's Report*

WIL Research Laboratories, LLC
401(k) Plan

Financial Statements and Supplemental Schedules

May 1, 2017 and December 31, 2016 and 2015 and for the period January 1, 2017
through May 1, 2017 and for the year ended December 31, 2016

Contents

Independent Auditor's Report	1
------------------------------------	---

Financial Statements

Statements of Net Assets Available for Benefits	3
Statements of Changes in Net Assets Available for Benefits.....	4
Notes to Financial Statements	5

Supplemental Schedules

Schedule H, line 4a-Schedule of Delinquent Participant Contributions for the year ended December 31, 2016.....	17
Schedule H, line 4i-Schedule of Assets (Held At End of Year) December 31, 2016	18



DG Krause LLC
7862 Shady Woods Dr
Indianapolis, Indiana 46259

Phone: (317) 245-7932
www.dgkllc.com

Independent Auditor's Report

Plan Administrator of
WIL Research Laboratories, LLC 401(k) Plan

Report on the Financial Statements

We were engaged to audit the accompanying financial statements of the WIL Research Laboratories, LLC 401(k) Plan (the Plan), which comprise the statements of net assets available for benefits as of May 1, 2017 and December 31, 2016 and 2015, and the related statements of changes in net assets available for benefits for the period from January 1, 2017 through May 1, 2017 and for the year ended December 31, 2016, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on conducting the audit in accordance with auditing standards generally accepted in the United States of America. Because of the matter described in the Basis for Disclaimer of Opinion paragraph, however, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion.

Basis for Disclaimer of Opinion

As permitted by 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974, the plan administrator instructed us not to perform, and we did not perform, any auditing procedures with respect to the information summarized in Note 3, which was certified by Wells Fargo Bank, N.A., the trustee of the Plan, except for comparing such information with the related information included in the financial statements. We have been informed by the plan administrator that the trustee holds the Plan's investment assets and executes investment transactions. The plan administrator has obtained a certification from the trustee as of May 1, 2017 and December 31, 2016 and 2015, and for period from January 1, 2017

through May 1, 2017 and for the year ended December 31, 2016, that the information provided to the plan administrator by the trustee is complete and accurate.

Disclaimer of Opinion

Because of the significance of the matter described in the Basis for Disclaimer of Opinion paragraph, we have not been able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion. Accordingly, we do not express an opinion on these financial statements.

Emphasis of Matter Relating to Plan Merger

The Plan merged into the Charles River Laboratories, Inc. Savings/Plus Plan effective May 1, 2017. See Note 1.

Other Matter Supplemental Schedules

The supplemental Schedule H, line 4a – Schedule of Delinquent Participant Contributions for the year ended December 31, 2016 and Schedule H, line 4i – Schedule of Assets (Held At End of Year) as of December 31, 2016, are required by the Department of Labor's (DOL) Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974 and are presented for the purpose of additional analysis and are not a required part of the financial statements. Because of the significance of the matter described in the Basis for Disclaimer of Opinion paragraph, we do not express an opinion on the supplemental schedules.

Report on Form and Content in Compliance with DOL Rules and Regulations

The form and content of the information included in the financial statements and supplemental schedules, other than that derived from the information certified by the trustee, have been audited by us in accordance with auditing standards generally accepted in the United States of America and, in our opinion, are presented in compliance with the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974.



Indianapolis, Indiana
March 14, 2018

WIL Research Laboratories, LLC
401(k) Plan

Statements of Net Assets Available for Benefits

	May 1	December 31	
	2017	2016	2015
Assets			
Investments, at fair value	\$ -	\$ 45,348,506	\$ 38,520,842
Cash	-	128	631
Contributions receivable from participants	-	-	550
Contributions receivable from employer	-	-	1,147
Other receivable	-	-	3,478
Notes receivable from participants	-	985,617	1,072,948
Total assets	-	46,334,251	39,599,596
Liabilities			
Excess contributions refundable	-	-	923
Accrued administrative expenses	-	28,832	25,169
Total liabilities	-	28,832	26,092
Net assets available for benefits	\$ -	\$46,305,419	\$39,573,504

See accompanying notes to financial statements.

WIL Research Laboratories, LLC
401(k) Plan

Statements of Changes in Net Assets Available for Benefits

	Period from January 1, 2017 through May 1, 2017	Year ended December 31, 2016
Additions:		
Contributions:		
Participants	\$ 1,135,487	\$ 3,829,767
Rollovers	29,945	187,172
Employer	556,150	1,953,021
	<u>1,721,582</u>	<u>5,969,960</u>
Net realized and unrealized appreciation in fair value of investments	2,851,457	3,423,495
Investment income	86,582	648,848
Interest income on notes receivable from participants	10,341	41,660
Total additions	<u>4,669,962</u>	<u>10,083,963</u>
Deductions:		
Benefits paid	(1,254,592)	(3,182,299)
Administrative expenses	(53,634)	(169,749)
Total deductions	<u>(1,308,226)</u>	<u>(3,352,048)</u>
Net increase	3,361,736	6,731,915
Transfers to other plans	(49,667,155)	-
Net assets available for benefits at beginning of year	<u>46,305,419</u>	<u>39,573,504</u>
Net assets available for benefits at end of year	<u>\$ -</u>	<u>\$ 46,305,419</u>

See accompanying notes to financial statements.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements

May 1, 2017 and December 31, 2016

1. Description of the Merged Plan

The following brief description of the WIL Research Laboratories, LLC 401(k) Plan (the Plan) is provided for general information purposes only. Participants should refer to the Summary Plan Description for more complete information.

Current Developments

On April 4, 2016 Charles River Laboratories, International, Inc. acquired WIL Research Laboratories, LLC and the other related entities that participate in the Plan.

On April 27, 2016 the Plan Sponsor provided written notice to Wells Fargo Bank, N.A. of its desire to redeem the Plan's investment in the Wells Fargo Stable Return Fund N. The fund has a 12 month redemption notice period, unless waived. In April 2017, following the redemption notice period, the investment in the fund was redeemed at its net asset value (NAV), with no reduction in value incurred by the Plan.

On June 24, 2016 the legal names of the following entities that participate in the Plan were changed as indicated below:

Former legal name	New legal name
WIL Research Laboratories, LLC	Charles River Laboratories Ashland, LLC
WIL Research-Skokie, LLC	Charles River Laboratories Skokie, LLC
QS Pharma, LLC	Charles River Laboratories Contract Manufacturing PA, LLC
WIL Research –Hillsborough, LLC	Charles River Laboratories Hillsborough, LLC
WIL Research Company, Inc.	Charles River Laboratories SA USA, Inc.

Effective December 31, 2016, Charles River Laboratories Hillsborough, LLC ceased to be a participating employer in the Plan. Effective April 2, 2017 Charles River Laboratories Skokie, LLC merged into Charles River Laboratories Ashland, LLC.

Plan Freeze

Effective April 1, 2017 the Plan was amended to freeze the Plan. All contributions to the Plan were ceased. Participants remained fully vested in their accounts within the Plan. Also, effective April 1, 2017 certain participants of the Plan became eligible to participate in the Charles River Laboratories, Inc. Savings/Plus Plan.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements

May 1, 2017 and December 31, 2016

1. Description of the Merged Plan (continued)

Plan Spin-off

Effective February 9, 2017, Charles River Laboratories Contract Manufacturing PA, LLC was sold to an independent third party. Concurrent with the sale, Charles River Laboratories Contract Manufacturing PA, LLC ceased to be a participating employer in the Plan. Effective April 1, 2017, Charles River Laboratories SA USA, Inc. also ceased to be a participating employer in the Plan.

Following the transaction to sell the entity described above, effective May 1, 2017 the individual participant accounts of the Plan for certain participants, who had been employed by Charles River Laboratories Contract Manufacturing PA, LLC, were spun-off to a newly formed ERISA plan named QS Pharma LLC 401(k) Plan. As a result of this spin-off, investments of \$4,135,210 and notes receivable from participants of \$68,261 were transferred from the Plan to the QS Pharma LLC 401(k) Plan on May 1, 2017. The QS Pharma LLC 401(k) Plan was subsequently renamed Quotient Sciences – Philadelphia, LLC 401(k) Plan through a plan amendment effective December 31, 2017.

Plan Merger

Effective May 1, 2017, the Plan merged into the Charles River Laboratories, Inc. Savings/Plus Plan. As a result of this plan merger, investments of \$44,526,205 and notes receivable from participants of \$937,479 were transferred from the Plan to the Charles River Laboratories, Inc. Savings/Plus Plan on May 1, 2017. Following this transaction the Plan had no remaining net assets available for benefits.

General

The Plan was established January 1, 2005. The Plan is a voluntary defined contribution plan covering all employees (except employees represented by a bargaining unit, non-resident aliens, leased employees, and independent contractors or their employees who are later determined by the IRS to be an employee) of Charles River Laboratories Ashland, LLC (Company). For the year ended December 31, 2016, employees of Charles River Laboratories Skokie, LLC, Charles River Laboratories Contract Manufacturing PA, LLC, Charles River Laboratories Hillsborough, LLC, and Charles River Laboratories SA USA Inc., members of the controlled group including Charles River Laboratories Ashland, LLC, were also eligible to participate in the Plan. Entry into the Plan is the first day of the Plan

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements

May 1, 2017 and December 31, 2016

1. Description of the Merged Plan (continued)

General (continued)

quarter following the date that eligibility requirements are satisfied. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA), as amended.

Contributions

Plan participants may contribute up to 100 percent of their pretax annual compensation, as defined in the Plan, subject to certain Internal Revenue Code limitations. The Company contributes 100 percent of the first 3 percent of pretax annual compensation that a participant contributes to the Plan, plus 50 percent of participant contributions which are over 3 percent of pay but not over 5 percent of pay. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans. The Plan includes an automatic deferral feature. Accordingly, 3% of eligible compensation will be automatically deferred for participants who do not elect an alternative deferral amount or elect not to defer. The automatic deferral amount will increase 1% on July 1 of each plan year, up to a maximum of 8%, unless the participant opts out of the automatic increase.

Effective July 1, 2014, for every participant deferring between 1% and 7% of eligible compensation, there was and will be an increase by 1% on the first day of July each Plan year until a maximum deferral percentage of 8% is reached. A participant who elects to opt out of the automatic increase shall not be subject to the annual increase in subsequent years.

Vesting

Participants are always 100% vested in their total account.

Participant Accounts and Investment Options

Individual accounts are maintained for each Plan participant. Each participant's account is credited with the participant's contribution, the Company's matching contribution, and Plan earnings, and charged with withdrawals and an allocation of Plan losses. Allocations are based on participant earnings or account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account. All amounts in participant accounts are participant-directed.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements

May 1, 2017 and December 31, 2016

1. Description of the Merged Plan (continued)

Notes Receivable from Participants

Participants may only have one loan outstanding from the Plan at a time and may borrow from their accounts a minimum of \$1,000 up to a maximum equal to the lesser of \$50,000 or 50% of their vested account balance, whichever is less. The loans are secured by the balance in the participant's account and bear interest at rates commensurate with local prevailing rates as determined quarterly by the Plan administrator. Principal and interest is paid ratably through payroll deductions.

Payment of Benefits

On termination of service due to death, disability, or retirement, the Plan provides for a lump-sum amount equal to the value of the participant's vested interest in his or her account. For termination of service for other reasons, a participant may receive the value of the vested interest in his or her account as a lump-sum distribution.

Unallocated Accounts

As of December 31, 2016 and 2015, approximately \$65,500 and \$138,500, respectively, of reported net assets available for benefits of the Plan, which have not been allocated to specific participant accounts, are temporarily maintained in an ERISA Account. These amounts, which have been reported as net appreciation in fair value of investments, originate through the rebating to the Plan by Wells Fargo Bank, N.A., the trustee, revenue sharing amounts it receives relating to the Plan's mutual fund investments. During the plan year ended December 31, 2016, approximately \$73,000 was credited to individual participant accounts from the ERISA Account. An unallocated amount of approximately \$50,700 was included in the amount of net assets transferred to the Charles River Laboratories, Inc. Savings/Plus Plan as part of the Plan merger and will be used in the future to pay expenses or be credited to individual participant accounts through earnings allocations.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

2. Summary of Significant Accounting Policies

Use of Estimates and Basis of Accounting

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires Plan management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.

The financial statements of the Plan are prepared on the accrual basis of accounting.

Investment Valuation and Income Recognition

The Plan's investments are stated at fair value. Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. See Note 4 for discussion of fair value measurements.

Notes Receivable from Participants

Notes receivable from participants are measured and reported at unpaid principal balance plus accrued but unpaid interest. Delinquent notes receivable from participants are recorded as a distribution based upon the terms of the plan document.

Risks and Uncertainties

The Plan invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the value of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the statements of net assets available for benefits.

Expenses of the Plan

Certain expenses of administering the Plan and the related Plan assets are paid by the Company. Participants are charged fees for certain participant initiated transactions.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Payment of Benefits

Benefit payments to participants are recorded upon distribution.

Subsequent Events

Subsequent events were evaluated through March 14, 2018, which is the date the financial statements were available to be issued.

3. Investments and Notes Receivable from Participants

All investment information disclosed in the accompanying financial statements and schedules, including investments at December 31, 2016 and 2015, notes receivable from participants at December 31, 2016 and 2015 and investment income, net appreciation in fair value of investments and interest income on notes receivable from participants for the period January 1, 2017 through May 1, 2017 and for the year ended December 31, 2016, was obtained or derived from information supplied to the Plan administrator and certified as complete and accurate by Wells Fargo Bank, N.A., the trustee of the Plan.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

4. Fair Value Measurements

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3). The three levels of the fair value hierarchy under Topic 820 are described as follows:

Level 1	Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
Level 2	Inputs to the valuation methodology include • quoted prices for similar assets or liabilities in active markets; • quoted prices for identical or similar assets or liabilities in inactive markets; • inputs other than quoted prices that are observable for the asset or liability; • inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.
Level 3	Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at December 31, 2016 and 2015. There were no assets held as of May 1, 2017 following the merger of the Plan disclosed in Note 1.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

4. Fair Value Measurements (continued)

The mutual funds are valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the U.S. Securities and Exchange Commission. These funds are required to publish their daily net asset value and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

The stable value collective trust fund is composed primarily of fully benefit-responsive investment contracts that is valued at the net asset value of units of the bank collective trust. The net asset value is used as a practical expedient to estimate fair value. This practical expedient would not be used if it is determined to be probable that the fund will sell the investment for an amount different from the reported net asset value. Participant transactions (purchases and sales) may occur daily. If the Plan initiates a full redemption of the collective trust, the issuer reserves the right to require 12 months' notification to ensure that security liquidations will be carried out in an orderly business manner. See Note 1.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

4. Fair Value Measurements (continued)

The following table sets forth by level, within the fair value hierarchy, the Plan's assets at fair value as of December 31, 2016:

	Level 1	Level 2	Level 3	Total
Mutual funds	\$44,010,280	\$ -	\$ -	\$ 44,010,280
Investments measured at net asset value (a)	-	-	-	1,338,226
Investments at fair value	\$44,010,280	\$ -	\$ -	\$ 45,348,506

The following table sets forth by level, within the fair value hierarchy, the Plan's assets at fair value as of December 31, 2015:

	Level 1	Level 2	Level 3	Total
Mutual funds	\$37,097,050	\$ -	\$ -	\$ 37,097,050
Investments measured at net asset value (a)	-	-	-	1,423,792
Investments at fair value	\$37,097,050	\$ -	\$ -	\$ 38,520,842

(a) In accordance with Subtopic 820-10, certain investments that were measured at net asset value per share (or its equivalent) have not been classified in the fair value hierarchy. The fair value amounts presented in this table for those investments are intended to permit reconciliation of the fair value of those assets classified in the hierarchy table to the line items presented in the statements of net assets available for benefits.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

4. Fair Value Measurements (continued)

Fair Value of Investments in Entities that Use Net Asset Value

The following table summarizes investments measured at fair value based on net asset value (NAVs) per share as of December 31, 2016:

December 31, 2016	Fair Value	Unfunded Commitments	Redemption Frequency (if currently eligible)	Redemption Notice Period
Collective trust fund – Wells Fargo Stable Return Fund N	\$1,338,226	n/a	Daily	12 months written notice, which at the discretion of Wells Fargo may be waived. See Note 1.

The following table summarizes investments measured at fair value based on net asset value (NAVs) per share as of December 31, 2015:

December 31, 2015	Fair Value	Unfunded Commitments	Redemption Frequency (if currently eligible)	Redemption Notice Period
Collective trust fund – Wells Fargo Stable Return Fund N	\$1,423,792	n/a	Daily	12 months written notice, which at the discretion of Wells Fargo may be waived

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

5. Income Tax Status

The Plan was restated effective January 1, 2016. The underlying volume submitter profit sharing plan with CODA, which was adopted with this plan restatement, has received an opinion letter from the IRS dated March 31, 2014 stating that the form of the plan is qualified under section 401 of the Code, and therefore the related trust is tax exempt. In accordance with Revenue Procedure 2011-49, 2011-44 I.R.B.608 the Company has determined that it is eligible to and has chosen to rely on the current IRS volume submitter opinion letter. Once qualified, the Plan is required to operate in conformity with the Code to maintain its qualification. The Plan Sponsor believes that they have operated and merged the Plan in a manner that has not jeopardized the qualified status of the Plan.

Accounting principles generally accepted in the United States of America require plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of May 1, 2017, there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

6. Plan Termination

The Company had the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions set forth in ERISA. See Note 1.

7. Transactions with Parties in Interest

The Plan invests in a collective trust fund and mutual fund sponsored by affiliates of the Plan's trustee, who is a party in interest. Such transactions represent statutorily exempt transactions.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

8. Reconciliation of Financial Statements to Form 5500

The following is a reconciliation of net assets available for benefits per the financial statements to the Form 5500:

	December 31 2016	December 31 2015
Net assets available for benefits per the financial statements	\$46,305,419	\$39,573,504
Less contributions receivable from employer	-	(1,147)
Less contributions receivable from participants	-	(550)
Less other receivable	-	(3,478)
Add accrued administrative expenses	28,832	25,169
Add excess contributions refundable	-	923
Net assets available for benefits per Form 5500	<u>\$46,334,251</u>	<u>\$39,594,421</u>

The following is a reconciliation of changes in net assets available for benefits per the financial statements to the Form 5500:

	Year Ended December 31 2016
Net increase in net assets available for benefits per the financial statements	\$ 6,731,915
Add net change in contributions receivable from employer	1,147
Add net change in contributions receivable from participants	550
Add net change in other receivable	3,478
Less net change in excess contributions refundable	(923)
Add net change in accrued administrative expenses	3,663
Net increase per the Form 5500	<u>\$ 6,739,830</u>

Certain differences result from the financial statements being prepared on the accrual basis of accounting and the Form 5500 being prepared on a modified cash basis. Accordingly, the net increase in net assets available for benefits, prior to transfers of assets from this Plan for the period from January 1, 2017 through May 1, 2017 was \$28,832 less for Form 5500 purposes than for financial statement purposes, as a result of the modified cash basis recognition of administrative expenses during the period for Form 5500 purposes.

Supplemental Schedules

WIL Research Laboratories, LLC 401(k) Plan

Schedule H, line 4a – Schedule of Delinquent Participant Contributions
Year ended December 31, 2016

EIN#: 26-0564612

Plan #: 001

Participant Contributions Transferred Late to Plan	Total that Constitute Nonexempt Prohibited Transactions			Total Fully Corrected under VFCP and PTE 2002-51
Check here if Late Participant Loan Repayments are included: ☒	Contributions Not Corrected	Contributions Corrected Outside VFCP	Contributions Pending Correction in VFCP	
\$ 10,621	\$ -	\$ 10,621	\$ -	\$ -

WIL Research Laboratories, LLC
401(k) Plan

Schedule H, line 4i–Schedule of Assets (Held At End of Year)

December 31, 2016

EIN #: 26-0564612

Plan #: 001

Identity of Issue, Borrower Lessor or Similar Party	Description of Investment Including Maturity Date, Rate of Interest, Par or Maturity Value	Current Value
Collective Trust Fund:		
*Wells Fargo Stable Return Fund N	25,111 Units	\$ 1,338,226
Mutual Funds:		
COLUMBIA LARGE CAP INDEX Z	79,005 Shares	3,385,380
JP MORGAN SMART RETIREMENT INCOME A	39,052 Shares	677,947
TEMPLETON GLOBAL BOND A	47,575 Shares	570,904
PUTNAM GROWTH OPPORTUNITIES Y	80,201 Shares	2,033,902
JP MORGAN SMART RETIREMENT 2015 A	1,970 Shares	34,250
JP MORGAN SMART RETIREMENT 2020 A	176,641 Shares	3,190,129
JP MORGAN SMART RETIREMENT 2025 A	38,595 Shares	675,413
JP MORGAN SMART RETIREMENT 2030 A	311,922 Shares	5,851,660
JP MORGAN SMART RETIREMENT 2035 A	26,257 Shares	472,108
JP MORGAN SMART RETIREMENT 2040 A	284,405 Shares	5,483,330
JP MORGAN SMART RETIREMENT 2045 A	34,011 Shares	621,379
JP MORGAN SMART RETIREMENT 2050 A	260,810 Shares	4,754,569
JP MORGAN SMART RETIREMENT 2055 A	32,095 Shares	651,208
COLUMBIA SMALL CAP INDEX Z	143,441 Shares	3,396,685
BLACKROCK HIGH YIELD PORTFOLIO A	50,660 Shares	386,539
AMERICAN BEACON SMALL CAP VALUE/ADVISOR	55,393 Shares	1,462,381
BLACKROCK EQUITY DIVIDEND A	90,574 Shares	2,037,915
JP MORGAN MID CAP GROWTH FUND A	47,205 Shares	1,144,721
METROPOLITAN WEST TOTAL RETURN BOND M	187,058 Shares	1,971,595
OPPENHEIMER DEVELOPING MKTS FUND A	9,250 Shares	299,886
*WELLS FARGO SPECIAL MID CAP VALUE A	58,470 Shares	2,056,382
OAKMARK INTERNATIONAL II	101,731 Shares	2,323,543
QM US SMALL CAP GROWTH EQUITY	18,477 Shares	528,454
		<u>44,010,280</u>
Participant Loans	Loans to Participants, \$985,617 principal amount and accrued interest, various maturity dates and each loan with a 4.25%-4.75% interest rate	985,617
		<u><u>\$ 46,334,123</u></u>

* Indicates a party-in-interest to the Plan.

Note: Cost data is not required to be presented for participant-directed investments.

Financial Statements and Supplemental Schedules

WIL Research Laboratories, LLC
401(k) Plan

*May 1, 2017 and December 31, 2016 and 2015 and for the period from January 1, 2017 through
May 1, 2017 and for the year ended December 31, 2016 with Independent Auditor's Report*

WIL Research Laboratories, LLC
401(k) Plan

Financial Statements and Supplemental Schedules

May 1, 2017 and December 31, 2016 and 2015 and for the period January 1, 2017
through May 1, 2017 and for the year ended December 31, 2016

Contents

Independent Auditor's Report	1
------------------------------------	---

Financial Statements

Statements of Net Assets Available for Benefits	3
Statements of Changes in Net Assets Available for Benefits.....	4
Notes to Financial Statements	5

Supplemental Schedules

Schedule H, line 4a-Schedule of Delinquent Participant Contributions for the year ended December 31, 2016.....	17
Schedule H, line 4i-Schedule of Assets (Held At End of Year) December 31, 2016	18



DG Krause LLC
7862 Shady Woods Dr
Indianapolis, Indiana 46259

Phone: (317) 245-7932
www.dgkllc.com

Independent Auditor's Report

Plan Administrator of
WIL Research Laboratories, LLC 401(k) Plan

Report on the Financial Statements

We were engaged to audit the accompanying financial statements of the WIL Research Laboratories, LLC 401(k) Plan (the Plan), which comprise the statements of net assets available for benefits as of May 1, 2017 and December 31, 2016 and 2015, and the related statements of changes in net assets available for benefits for the period from January 1, 2017 through May 1, 2017 and for the year ended December 31, 2016, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on conducting the audit in accordance with auditing standards generally accepted in the United States of America. Because of the matter described in the Basis for Disclaimer of Opinion paragraph, however, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion.

Basis for Disclaimer of Opinion

As permitted by 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974, the plan administrator instructed us not to perform, and we did not perform, any auditing procedures with respect to the information summarized in Note 3, which was certified by Wells Fargo Bank, N.A., the trustee of the Plan, except for comparing such information with the related information included in the financial statements. We have been informed by the plan administrator that the trustee holds the Plan's investment assets and executes investment transactions. The plan administrator has obtained a certification from the trustee as of May 1, 2017 and December 31, 2016 and 2015, and for period from January 1, 2017

through May 1, 2017 and for the year ended December 31, 2016, that the information provided to the plan administrator by the trustee is complete and accurate.

Disclaimer of Opinion

Because of the significance of the matter described in the Basis for Disclaimer of Opinion paragraph, we have not been able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion. Accordingly, we do not express an opinion on these financial statements.

Emphasis of Matter Relating to Plan Merger

The Plan merged into the Charles River Laboratories, Inc. Savings/Plus Plan effective May 1, 2017. See Note 1.

Other Matter Supplemental Schedules

The supplemental Schedule H, line 4a – Schedule of Delinquent Participant Contributions for the year ended December 31, 2016 and Schedule H, line 4i – Schedule of Assets (Held At End of Year) as of December 31, 2016, are required by the Department of Labor's (DOL) Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974 and are presented for the purpose of additional analysis and are not a required part of the financial statements. Because of the significance of the matter described in the Basis for Disclaimer of Opinion paragraph, we do not express an opinion on the supplemental schedules.

Report on Form and Content in Compliance with DOL Rules and Regulations

The form and content of the information included in the financial statements and supplemental schedules, other than that derived from the information certified by the trustee, have been audited by us in accordance with auditing standards generally accepted in the United States of America and, in our opinion, are presented in compliance with the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974.



Indianapolis, Indiana
March 14, 2018

WIL Research Laboratories, LLC
401(k) Plan

Statements of Net Assets Available for Benefits

	May 1	December 31	
	2017	2016	2015
Assets			
Investments, at fair value	\$ -	\$ 45,348,506	\$ 38,520,842
Cash	-	128	631
Contributions receivable from participants	-	-	550
Contributions receivable from employer	-	-	1,147
Other receivable	-	-	3,478
Notes receivable from participants	-	985,617	1,072,948
Total assets	-	46,334,251	39,599,596
Liabilities			
Excess contributions refundable	-	-	923
Accrued administrative expenses	-	28,832	25,169
Total liabilities	-	28,832	26,092
Net assets available for benefits	\$ -	\$46,305,419	\$39,573,504

See accompanying notes to financial statements.

WIL Research Laboratories, LLC
401(k) Plan

Statements of Changes in Net Assets Available for Benefits

	Period from January 1, 2017 through May 1, 2017	Year ended December 31, 2016
Additions:		
Contributions:		
Participants	\$ 1,135,487	\$ 3,829,767
Rollovers	29,945	187,172
Employer	556,150	1,953,021
	<u>1,721,582</u>	<u>5,969,960</u>
Net realized and unrealized appreciation in fair value of investments	2,851,457	3,423,495
Investment income	86,582	648,848
Interest income on notes receivable from participants	10,341	41,660
Total additions	<u>4,669,962</u>	<u>10,083,963</u>
Deductions:		
Benefits paid	(1,254,592)	(3,182,299)
Administrative expenses	(53,634)	(169,749)
Total deductions	<u>(1,308,226)</u>	<u>(3,352,048)</u>
Net increase	3,361,736	6,731,915
Transfers to other plans	(49,667,155)	-
Net assets available for benefits at beginning of year	<u>46,305,419</u>	<u>39,573,504</u>
Net assets available for benefits at end of year	<u>\$ -</u>	<u>\$ 46,305,419</u>

See accompanying notes to financial statements.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements

May 1, 2017 and December 31, 2016

1. Description of the Merged Plan

The following brief description of the WIL Research Laboratories, LLC 401(k) Plan (the Plan) is provided for general information purposes only. Participants should refer to the Summary Plan Description for more complete information.

Current Developments

On April 4, 2016 Charles River Laboratories, International, Inc. acquired WIL Research Laboratories, LLC and the other related entities that participate in the Plan.

On April 27, 2016 the Plan Sponsor provided written notice to Wells Fargo Bank, N.A. of its desire to redeem the Plan's investment in the Wells Fargo Stable Return Fund N. The fund has a 12 month redemption notice period, unless waived. In April 2017, following the redemption notice period, the investment in the fund was redeemed at its net asset value (NAV), with no reduction in value incurred by the Plan.

On June 24, 2016 the legal names of the following entities that participate in the Plan were changed as indicated below:

Former legal name	New legal name
WIL Research Laboratories, LLC	Charles River Laboratories Ashland, LLC
WIL Research-Skokie, LLC	Charles River Laboratories Skokie, LLC
QS Pharma, LLC	Charles River Laboratories Contract Manufacturing PA, LLC
WIL Research –Hillsborough, LLC	Charles River Laboratories Hillsborough, LLC
WIL Research Company, Inc.	Charles River Laboratories SA USA, Inc.

Effective December 31, 2016, Charles River Laboratories Hillsborough, LLC ceased to be a participating employer in the Plan. Effective April 2, 2017 Charles River Laboratories Skokie, LLC merged into Charles River Laboratories Ashland, LLC.

Plan Freeze

Effective April 1, 2017 the Plan was amended to freeze the Plan. All contributions to the Plan were ceased. Participants remained fully vested in their accounts within the Plan. Also, effective April 1, 2017 certain participants of the Plan became eligible to participate in the Charles River Laboratories, Inc. Savings/Plus Plan.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements

May 1, 2017 and December 31, 2016

1. Description of the Merged Plan (continued)

Plan Spin-off

Effective February 9, 2017, Charles River Laboratories Contract Manufacturing PA, LLC was sold to an independent third party. Concurrent with the sale, Charles River Laboratories Contract Manufacturing PA, LLC ceased to be a participating employer in the Plan. Effective April 1, 2017, Charles River Laboratories SA USA, Inc. also ceased to be a participating employer in the Plan.

Following the transaction to sell the entity described above, effective May 1, 2017 the individual participant accounts of the Plan for certain participants, who had been employed by Charles River Laboratories Contract Manufacturing PA, LLC, were spun-off to a newly formed ERISA plan named QS Pharma LLC 401(k) Plan. As a result of this spin-off, investments of \$4,135,210 and notes receivable from participants of \$68,261 were transferred from the Plan to the QS Pharma LLC 401(k) Plan on May 1, 2017. The QS Pharma LLC 401(k) Plan was subsequently renamed Quotient Sciences – Philadelphia, LLC 401(k) Plan through a plan amendment effective December 31, 2017.

Plan Merger

Effective May 1, 2017, the Plan merged into the Charles River Laboratories, Inc. Savings/Plus Plan. As a result of this plan merger, investments of \$44,526,205 and notes receivable from participants of \$937,479 were transferred from the Plan to the Charles River Laboratories, Inc. Savings/Plus Plan on May 1, 2017. Following this transaction the Plan had no remaining net assets available for benefits.

General

The Plan was established January 1, 2005. The Plan is a voluntary defined contribution plan covering all employees (except employees represented by a bargaining unit, non-resident aliens, leased employees, and independent contractors or their employees who are later determined by the IRS to be an employee) of Charles River Laboratories Ashland, LLC (Company). For the year ended December 31, 2016, employees of Charles River Laboratories Skokie, LLC, Charles River Laboratories Contract Manufacturing PA, LLC, Charles River Laboratories Hillsborough, LLC, and Charles River Laboratories SA USA Inc., members of the controlled group including Charles River Laboratories Ashland, LLC, were also eligible to participate in the Plan. Entry into the Plan is the first day of the Plan

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements

May 1, 2017 and December 31, 2016

1. Description of the Merged Plan (continued)

General (continued)

quarter following the date that eligibility requirements are satisfied. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA), as amended.

Contributions

Plan participants may contribute up to 100 percent of their pretax annual compensation, as defined in the Plan, subject to certain Internal Revenue Code limitations. The Company contributes 100 percent of the first 3 percent of pretax annual compensation that a participant contributes to the Plan, plus 50 percent of participant contributions which are over 3 percent of pay but not over 5 percent of pay. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans. The Plan includes an automatic deferral feature. Accordingly, 3% of eligible compensation will be automatically deferred for participants who do not elect an alternative deferral amount or elect not to defer. The automatic deferral amount will increase 1% on July 1 of each plan year, up to a maximum of 8%, unless the participant opts out of the automatic increase.

Effective July 1, 2014, for every participant deferring between 1% and 7% of eligible compensation, there was and will be an increase by 1% on the first day of July each Plan year until a maximum deferral percentage of 8% is reached. A participant who elects to opt out of the automatic increase shall not be subject to the annual increase in subsequent years.

Vesting

Participants are always 100% vested in their total account.

Participant Accounts and Investment Options

Individual accounts are maintained for each Plan participant. Each participant's account is credited with the participant's contribution, the Company's matching contribution, and Plan earnings, and charged with withdrawals and an allocation of Plan losses. Allocations are based on participant earnings or account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account. All amounts in participant accounts are participant-directed.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements

May 1, 2017 and December 31, 2016

1. Description of the Merged Plan (continued)

Notes Receivable from Participants

Participants may only have one loan outstanding from the Plan at a time and may borrow from their accounts a minimum of \$1,000 up to a maximum equal to the lesser of \$50,000 or 50% of their vested account balance, whichever is less. The loans are secured by the balance in the participant's account and bear interest at rates commensurate with local prevailing rates as determined quarterly by the Plan administrator. Principal and interest is paid ratably through payroll deductions.

Payment of Benefits

On termination of service due to death, disability, or retirement, the Plan provides for a lump-sum amount equal to the value of the participant's vested interest in his or her account. For termination of service for other reasons, a participant may receive the value of the vested interest in his or her account as a lump-sum distribution.

Unallocated Accounts

As of December 31, 2016 and 2015, approximately \$65,500 and \$138,500, respectively, of reported net assets available for benefits of the Plan, which have not been allocated to specific participant accounts, are temporarily maintained in an ERISA Account. These amounts, which have been reported as net appreciation in fair value of investments, originate through the rebating to the Plan by Wells Fargo Bank, N.A., the trustee, revenue sharing amounts it receives relating to the Plan's mutual fund investments. During the plan year ended December 31, 2016, approximately \$73,000 was credited to individual participant accounts from the ERISA Account. An unallocated amount of approximately \$50,700 was included in the amount of net assets transferred to the Charles River Laboratories, Inc. Savings/Plus Plan as part of the Plan merger and will be used in the future to pay expenses or be credited to individual participant accounts through earnings allocations.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

2. Summary of Significant Accounting Policies

Use of Estimates and Basis of Accounting

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires Plan management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.

The financial statements of the Plan are prepared on the accrual basis of accounting.

Investment Valuation and Income Recognition

The Plan's investments are stated at fair value. Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. See Note 4 for discussion of fair value measurements.

Notes Receivable from Participants

Notes receivable from participants are measured and reported at unpaid principal balance plus accrued but unpaid interest. Delinquent notes receivable from participants are recorded as a distribution based upon the terms of the plan document.

Risks and Uncertainties

The Plan invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the value of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the statements of net assets available for benefits.

Expenses of the Plan

Certain expenses of administering the Plan and the related Plan assets are paid by the Company. Participants are charged fees for certain participant initiated transactions.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Payment of Benefits

Benefit payments to participants are recorded upon distribution.

Subsequent Events

Subsequent events were evaluated through March 14, 2018, which is the date the financial statements were available to be issued.

3. Investments and Notes Receivable from Participants

All investment information disclosed in the accompanying financial statements and schedules, including investments at December 31, 2016 and 2015, notes receivable from participants at December 31, 2016 and 2015 and investment income, net appreciation in fair value of investments and interest income on notes receivable from participants for the period January 1, 2017 through May 1, 2017 and for the year ended December 31, 2016, was obtained or derived from information supplied to the Plan administrator and certified as complete and accurate by Wells Fargo Bank, N.A., the trustee of the Plan.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

4. Fair Value Measurements

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3). The three levels of the fair value hierarchy under Topic 820 are described as follows:

Level 1	Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
Level 2	Inputs to the valuation methodology include • quoted prices for similar assets or liabilities in active markets; • quoted prices for identical or similar assets or liabilities in inactive markets; • inputs other than quoted prices that are observable for the asset or liability; • inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.
Level 3	Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at December 31, 2016 and 2015. There were no assets held as of May 1, 2017 following the merger of the Plan disclosed in Note 1.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

4. Fair Value Measurements (continued)

The mutual funds are valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the U.S. Securities and Exchange Commission. These funds are required to publish their daily net asset value and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

The stable value collective trust fund is composed primarily of fully benefit-responsive investment contracts that is valued at the net asset value of units of the bank collective trust. The net asset value is used as a practical expedient to estimate fair value. This practical expedient would not be used if it is determined to be probable that the fund will sell the investment for an amount different from the reported net asset value. Participant transactions (purchases and sales) may occur daily. If the Plan initiates a full redemption of the collective trust, the issuer reserves the right to require 12 months' notification to ensure that security liquidations will be carried out in an orderly business manner. See Note 1.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

4. Fair Value Measurements (continued)

The following table sets forth by level, within the fair value hierarchy, the Plan's assets at fair value as of December 31, 2016:

	Level 1	Level 2	Level 3	Total
Mutual funds	\$44,010,280	\$ -	\$ -	\$ 44,010,280
Investments measured at net asset value (a)	-	-	-	1,338,226
Investments at fair value	\$44,010,280	\$ -	\$ -	\$ 45,348,506

The following table sets forth by level, within the fair value hierarchy, the Plan's assets at fair value as of December 31, 2015:

	Level 1	Level 2	Level 3	Total
Mutual funds	\$37,097,050	\$ -	\$ -	\$ 37,097,050
Investments measured at net asset value (a)	-	-	-	1,423,792
Investments at fair value	\$37,097,050	\$ -	\$ -	\$ 38,520,842

(a) In accordance with Subtopic 820-10, certain investments that were measured at net asset value per share (or its equivalent) have not been classified in the fair value hierarchy. The fair value amounts presented in this table for those investments are intended to permit reconciliation of the fair value of those assets classified in the hierarchy table to the line items presented in the statements of net assets available for benefits.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

4. Fair Value Measurements (continued)

Fair Value of Investments in Entities that Use Net Asset Value

The following table summarizes investments measured at fair value based on net asset value (NAVs) per share as of December 31, 2016:

December 31, 2016	Fair Value	Unfunded Commitments	Redemption Frequency (if currently eligible)	Redemption Notice Period
Collective trust fund – Wells Fargo Stable Return Fund N	\$1,338,226	n/a	Daily	12 months written notice, which at the discretion of Wells Fargo may be waived. See Note 1.

The following table summarizes investments measured at fair value based on net asset value (NAVs) per share as of December 31, 2015:

December 31, 2015	Fair Value	Unfunded Commitments	Redemption Frequency (if currently eligible)	Redemption Notice Period
Collective trust fund – Wells Fargo Stable Return Fund N	\$1,423,792	n/a	Daily	12 months written notice, which at the discretion of Wells Fargo may be waived

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

5. Income Tax Status

The Plan was restated effective January 1, 2016. The underlying volume submitter profit sharing plan with CODA, which was adopted with this plan restatement, has received an opinion letter from the IRS dated March 31, 2014 stating that the form of the plan is qualified under section 401 of the Code, and therefore the related trust is tax exempt. In accordance with Revenue Procedure 2011-49, 2011-44 I.R.B.608 the Company has determined that it is eligible to and has chosen to rely on the current IRS volume submitter opinion letter. Once qualified, the Plan is required to operate in conformity with the Code to maintain its qualification. The Plan Sponsor believes that they have operated and merged the Plan in a manner that has not jeopardized the qualified status of the Plan.

Accounting principles generally accepted in the United States of America require plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of May 1, 2017, there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

6. Plan Termination

The Company had the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions set forth in ERISA. See Note 1.

7. Transactions with Parties in Interest

The Plan invests in a collective trust fund and mutual fund sponsored by affiliates of the Plan's trustee, who is a party in interest. Such transactions represent statutorily exempt transactions.

WIL Research Laboratories, LLC
401(k) Plan

Notes to Financial Statements (continued)

8. Reconciliation of Financial Statements to Form 5500

The following is a reconciliation of net assets available for benefits per the financial statements to the Form 5500:

	December 31 2016	December 31 2015
Net assets available for benefits per the financial statements	\$46,305,419	\$39,573,504
Less contributions receivable from employer	-	(1,147)
Less contributions receivable from participants	-	(550)
Less other receivable	-	(3,478)
Add accrued administrative expenses	28,832	25,169
Add excess contributions refundable	-	923
Net assets available for benefits per Form 5500	<u>\$46,334,251</u>	<u>\$39,594,421</u>

The following is a reconciliation of changes in net assets available for benefits per the financial statements to the Form 5500:

	Year Ended December 31 2016
Net increase in net assets available for benefits per the financial statements	\$ 6,731,915
Add net change in contributions receivable from employer	1,147
Add net change in contributions receivable from participants	550
Add net change in other receivable	3,478
Less net change in excess contributions refundable	(923)
Add net change in accrued administrative expenses	3,663
Net increase per the Form 5500	<u>\$ 6,739,830</u>

Certain differences result from the financial statements being prepared on the accrual basis of accounting and the Form 5500 being prepared on a modified cash basis. Accordingly, the net increase in net assets available for benefits, prior to transfers of assets from this Plan for the period from January 1, 2017 through May 1, 2017 was \$28,832 less for Form 5500 purposes than for financial statement purposes, as a result of the modified cash basis recognition of administrative expenses during the period for Form 5500 purposes.

Supplemental Schedules

WIL Research Laboratories, LLC 401(k) Plan

Schedule H, line 4a – Schedule of Delinquent Participant Contributions
Year ended December 31, 2016

EIN#: 26-0564612

Plan #: 001

Participant Contributions Transferred Late to Plan	Total that Constitute Nonexempt Prohibited Transactions			Total Fully Corrected under VFCP and PTE 2002-51
Check here if Late Participant Loan Repayments are included: ☒	Contributions Not Corrected	Contributions Corrected Outside VFCP	Contributions Pending Correction in VFCP	
\$ 10,621	\$ -	\$ 10,621	\$ -	\$ -

WIL Research Laboratories, LLC
401(k) Plan

Schedule H, line 4i–Schedule of Assets (Held At End of Year)

December 31, 2016

EIN #: 26-0564612

Plan #: 001

Identity of Issue, Borrower Lessor or Similar Party	Description of Investment Including Maturity Date, Rate of Interest, Par or Maturity Value	Current Value
Collective Trust Fund:		
*Wells Fargo Stable Return Fund N	25,111 Units	\$ 1,338,226
Mutual Funds:		
COLUMBIA LARGE CAP INDEX Z	79,005 Shares	3,385,380
JP MORGAN SMART RETIREMENT INCOME A	39,052 Shares	677,947
TEMPLETON GLOBAL BOND A	47,575 Shares	570,904
PUTNAM GROWTH OPPORTUNITIES Y	80,201 Shares	2,033,902
JP MORGAN SMART RETIREMENT 2015 A	1,970 Shares	34,250
JP MORGAN SMART RETIREMENT 2020 A	176,641 Shares	3,190,129
JP MORGAN SMART RETIREMENT 2025 A	38,595 Shares	675,413
JP MORGAN SMART RETIREMENT 2030 A	311,922 Shares	5,851,660
JP MORGAN SMART RETIREMENT 2035 A	26,257 Shares	472,108
JP MORGAN SMART RETIREMENT 2040 A	284,405 Shares	5,483,330
JP MORGAN SMART RETIREMENT 2045 A	34,011 Shares	621,379
JP MORGAN SMART RETIREMENT 2050 A	260,810 Shares	4,754,569
JP MORGAN SMART RETIREMENT 2055 A	32,095 Shares	651,208
COLUMBIA SMALL CAP INDEX Z	143,441 Shares	3,396,685
BLACKROCK HIGH YIELD PORTFOLIO A	50,660 Shares	386,539
AMERICAN BEACON SMALL CAP VALUE/ADVISOR	55,393 Shares	1,462,381
BLACKROCK EQUITY DIVIDEND A	90,574 Shares	2,037,915
JP MORGAN MID CAP GROWTH FUND A	47,205 Shares	1,144,721
METROPOLITAN WEST TOTAL RETURN BOND M	187,058 Shares	1,971,595
OPPENHEIMER DEVELOPING MKTS FUND A	9,250 Shares	299,886
*WELLS FARGO SPECIAL MID CAP VALUE A	58,470 Shares	2,056,382
OAKMARK INTERNATIONAL II	101,731 Shares	2,323,543
QM US SMALL CAP GROWTH EQUITY	18,477 Shares	528,454
		44,010,280
Participant Loans	Loans to Participants, \$985,617 principal amount and accrued interest, various maturity dates and each loan with a 4.25%-4.75% interest rate	985,617
		\$ 46,334,123

* Indicates a party-in-interest to the Plan.

Note: Cost data is not required to be presented for participant-directed investments.